) excreted in urine obtained from nine subjects at various time intervals after the ingestion of 10-40 mg of both simple and compound codeine doses three times per day for three days were determined by gas chromatography-mass spectrometry analysis. 
Introduction
Ingestion of cold syrup containing codeine has frequently been reported (or claimed) to be the cause of positive morphine urine test results. This study, in which urinary excretion of morphine and codeine were monitored following the ingestion of opiate-containing materials, was conducted to add data to the literature base (1) (2) (3) (4) (5) (6) (7) .
In this study, ingestion patterns similar to those followed for therapeutical purposes were adopted with the hope that information generated by this study may be of reference value to help characterize codeine/morphine excretion patterns following the ingestion of codeine-containing cold syrup, which is currently a popular cold remedy in Taiwan.
Materials and Methods

Chemicals and reagents
Drug-free urine (blank urine) was purchased from Bio-Rad (Anaheim, CA). Nalorphine was purchased from Sigma Chemical (St. Louis, MO), and morphine and codeine solutions (1.0 mg/mL in methanol) were purchased from Radian International (Austin, TX). N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was purchased from Aldrich Chemical (Milwaukee, WI). Trishydroxymethylaminomethane was purchased from Riedel-deHaen A G (Seelze, Germany).
"Simple" and "compound" codeine syrup were prepared inhouse as described. Simple codeine syrup contained 1 mg codeine phosphate in each milliliter, and each milliliter of compound codeine syrup contained 2 mg of codeine phosphate, 2.5 mg of pseudoephedrine hydrochloride, and 0.4 mg of chlorpheniramine maleate.
Codeine intake and urine collection
The nature and purpose of this study were fully explained to the nine healthy male volunteers recruited for this study. They were instructed not to take any medicines for two weeks prior to the intake of the first dose. These nine volunteers were evenly divided into three groups that received 10-, 20-, and 40-rag codeine doses (simple codeine syrup), respectively. One dose was taken following each meal (three times per day) for three days, daytime only.
Urine was collected at 0, 1, 2, 4, and 6 h, then at every 6 (+ 1) h, until both codeine and morphine became undetectable (< 0.05 lJg/mL). Urine samples were collected in bottles, capped, and stored at -20~ until analysis.
Two weeks after the completion of the first experiment, another nine volunteers were again randomly divided into three groups of equal size, following the same intake practice, to receive 10-, 20-, and 40-rag codeine doses (compound codeine syrup), respectively.
(GC-MS) protocols, in which qualitative and quantitative analysis for codeine and morphine were performed.
Urine samples (4 mL) incorporating 5.00 IJg/mL internal standard (nalorphine) were then acid hydrolyzed in a screwcapped Pyrex glass tube with 0.5 mL 37% HCI at 121~ for 15 min. Solid-phase extraction (SPE) was performed using Chem Screen Cadan 203 SPE cartridges purchased from United Chemical Technology (Bristol, PA), following the procedures provided by the manufacturer (8) . Extracts were evaporated to dryness, then derivatized with the addition of 100 pL MSTFA (9) , vortex mixed for 20 s, and kept at 90~ for 10 min in a heating block.
Codeine and morphine recoveries of the extraction protocol were studied at four concentration levels (0.25, 0.50, 1.00, and 5.00 pg/mL of codeine or morphine) as described. One set of the standard solutions was prepared and processed through the extraction stage without adding the internal standard at the beginning. Internal standard aliquots were then added to the resulting extraction products. A second set of standards that contained the same amount of codeine (or morphine) included in the first set was prepared, and the same amount of the internal standard was added. Both sets were then processed (in parallel) through the derivatization and the GC-MS analysis stages. Recoveries were calculated by dividing the amounts of the analytes observed in the first set by that observed in the corresponding standards in the second set.
GC-MS analysis was performed using a Finnigan Witness System (Finnigan MAT, San Jose, CA) equipped with a Finnigan A200S autosampler, an HP LaserJet IV printer (HewlettPackard, Boise, ID), and a 30-m J&W Scientific (Folsom, CA) DB-5 fused-silica capillary column (0.25-mm i.d., 0.25-pm film thickness). One microliter of the derivatization product was injected using splitless mode with the injector maintained at 260~ and the GC-MS interface at 280~ The chromatographic system was operated under the following conditions: helium carrier gas head pressure, 10 psi; column temperature, initially at 200~ for 1 min, programmed to 280~ at 10~ then held for 5 min. Mass spectrometric parameters used were molecular ions m/z 371,429, and 455 for the confirmation of codeine, morphine, and nalorphine, respectively; area ratios of the total ion chromatogram (TIC) of codeine (or morphine) to nalorphine for quantitation.
To study the stability of the derivatization products, 1.00 IJg/mL codeine and morphine standard solutions were derivatized and stored in a refrigerator. OC-MS analyses were performed at 0-, 4-, 8-, 16-, 24-, and 48-h intervals.
Results
Representative TIC and full scan mass spectra resulting from the analytical protocol of a blank and a standard mixture containing codeine (1.0 pg/mL), morphine (1.0 pg/mL), and nalorphine (5.0 IJg/mL) are shown in Figure 1 .
The previously described analytical conditions provided the following linearity parameters for an eight-standard calibration set (0.10, 0.25, 0.50, 1.00, 5.00, 10.00, 20.00, 50.00 pg/mL): . Limits of detection (LOD) for both codeine and morphine were approximately 0.05 IJg/mL. Limits of quantitation (LOQ) for both codeine and morphine were at 0.1 IJg/mL. Extraction recoveries at the four concentration levels (0.25, 0.50, 1.00, 5.00 tJg/mL) studied were as follows: 83%, 85%, 86%, and 90% (average: 86%) for codeine and 79%, 81%, 81%, and 83% (average: 81%) for morphine. Derivatization products were found to be stable within 48 h. Using the amounts observed at the 0 h as the reference (1.00 lJg/mL), the amounts detected at the other five time internals (0, 4, 8, 16, 24, and 48 h) were as follows: 1.04, 1.07, 1.00, 1.00, and 1.05 ~tg/mL for derivatized codeine and 0.99, 0.98, 0.95, 1.06, and 0.99 t~g/mL for derivatized morphine.
Subject 3 dosing(h) collection(h) [C]* [M] [C]/[M] [C] [M] [C]/[M] [C] [M] [C]/[M]
Subject 6 dosing(h) collection(h) [C]* [M] [C]/[M] [C] [M] [C]/[M] [C] [M] [C]/[M]
Urinary excretion of codeine and morphine (and their ratios) following the adapted ingestion patterns of two different formula of codeine syrup are summarized in Tables I-VI. Duration of each phase for each subject is summarized in Table VII . It is interesting to note that no single individual exhibits all five codeine/morphine distribution characteristics during the entire excretion period and intervals monitored in this study. Part of the reason might have been simply a matter of the time of sample collection, that is, samples might not have been collected at a time when a certain distribution characteristic existed. The absence of excretion phases b, c, and d in subjects 3, 6, 7, 9, 13, 17, and 18 might have been an indication of poor codeine metabolizers (11) (12) (13) (14) .
Variations in time taken to reach phase b exist among subjects 1, 4, 12, and 14; time variations to reach phase c exist among subjects 2, 4, 5, 8, 11, 12, 15, and 16; and time variations to reach phase d exist among sub- jects 1, 2, 10, 11, 14, and 15. These observations are consistent with literature reports concerning polymorphic formation of morphine from codeine in poor and extensive metabolizers (11) (12) (13) (14) and was attributed by Cone et al. (6) to "genetic variation in cytochrome P-450 enzyme that catalyzed during oxidation." It was also observed that time taken to reach the end of phase a appears to depend on the dose size, but not the dose type (simple or compound) with the exceptions of subjects 3, 13, 14, and 15; time taken to reach the end of phase d also appears to depend on the dose size, but not the dose type with the exceptions of subjects 13, 14, and 15. Phase occurrence was generally in the order of a, b, c, d, e, except subject 8, in whom phase a occurred again following phase c at 30 h after the last dose.
The phenomenon that only morphine was detected in urine following codeine ingestion, as observed in subjects 1, 2, 10, 11, 14, and 15 in this study, has also been reported before (2, 4, 9) . Thus, the detection of morphine at 0.3 pg/mL (or less) without the presence of codeine (< 0.05 pg/mL) cannot be used alone as an indication of heroin or morphine use. 
Comparison with literature reports
One of the major goals of this study is to confirm literature reports related to the [C] and [M] distribution characteristics following the administration of various opiate-containing materials. Thus, observations resulting from this study are compared with earlier studies.
Yong and Lik (1) examined the urinary excretion patterns of morphine and codeine from a large group of subjects after ingestion of morphine, opium, codeine, or heroin and reported the following observations: 1. if [C]/[M] = 1.0-3.0, it is safe to say that codeine is involved, but it is not the only drug consumed--one or more of the drugs, such as morphine, heroin, opium, must have also been taken and 2. if the ratio falls below 1.0, heroin, illicit heroin, illicit morphine, opium, or morphine can be implicated as well as an admixture of any of these with codeine. Our data shown in Tables I-VI provided Ingestion of 10-40 mg of codeine in codeine-containing syrup three times per day (following each meal) for three days generated the following Although most of these data are consistent with the criteria reported in the literature for differentiating codeine or morphine/heroin ingestions, exceptions have also been observed. Thus, data hereby reported are valuable additions to the literature database helpful for the interpretation of analytical data related to the subject matter. 
Conclusions
